Location | Size | SUVmax | Tumor initial staging | Neoadjuvant therapy | |
---|---|---|---|---|---|
No.1 | 263R | 14.8 | 4.19 | II | – |
No.2a | 263R | 10.6 | 9.56 | III | + |
No.3a | 283 L | 15.2 | 10.28 | III | + |
No.4b | 263R | 15 | 11.13 | III | + |
No.5b | 263 L | 10.2 | 13.66 | III | + |
No.6 | 283R | 9 | 6.65 | III | + |
No.7 | 283R | 10.1 | 1.85 | IV | – |
No.8 | 283R | 5.1 | 0.78 | III | + |
No.9 | 263R | 9.8 | 1.85 | III | + |
No.10 | 283R | 10.3 | 2.20 | III | + |
No.11 | 263 L | 6.5 | 1.82 | III | – |
No.12 | 263 L | 6.6 | 1.58 | III | + |
No.13 | 283 L | 6.5 | 1.26 | II | + |
N0.14 | 283 L | 11.2 | 2.01 | II | + |
N0.15 | 283 L | 9 | 1.54 | III | + |
No.16 | 293 L | 4.8 | 1.13 | III | – |
N0.17 | 263 L | 10 | 1.91 | III | – |